Oova, a New York-based provider of women’s health and fertility solutions, raised $10.3M in Series A funding.
The round was led by Spero Ventures. Other investors included US Fertility, Virgin Group, Jefferson Health, Connecticut Innovations, Special Situations Life Sciences Fund, Samsung Next, Hannah Bronfman, and Sara Blakely.
The company intends to use the funds to expand operations and its business reach.
Led by Founder and CEO, Amy Divaraniya, Oova fully illuminates a woman’s fertility, giving her and her care team clear steps to conception. The company’s at-home urine test measures luteinizing hormone and progesterone to immediately inform a woman of her most fertile days and confirm ovulation and deliver personalized analytics and real-time action plans with every hormone reading.
It is FDA registered and allows its users to sync and share results with their doctor in real time. The Oova Kit launched in 2021 and has already trained its model on over 10,000 cycles monitored through the platform.
Key features of the Oova Membership include:
- Comprehensive Support: The membership grants access to the Oova Provider network, consisting of experienced healthcare professionals and hormone experts.
- Personalized Guidance: Women receive tailored recommendations from hormone experts through consultations.
- Community Connection: The Oova Membership fosters a vibrant and supportive community of like-minded women who are on similar journeys to parenthood. By engaging with this community, members can share their experiences, seek support, and forge valuable connections, creating a sense of camaraderie throughout their fertility journeys.
FinSMEs